NIH: Phase 3 Trial of Novavax Investigational COVID-19 Vaccine Opens
December 30, 2020
December 30, 2020
WASHINGTON, Dec. 30 (TNSRes) -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release:
The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine . . .
The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine . . .